Castle Biosciences, Inc.
CSTL
Updated: 24/09/2026, 18:02:26
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
No summaries found.
- Share price
- $34.08
- Market cap
- $1.04B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Derek J. Maetzold
- Employees
- 1,002
- IPO date
- 25/07/2019
- Beta
- 0.996
- Last dividend
- $0.00
- Day range
- $34.01 – $35.84
- 52-week range
- $17.72 – $44.28
- 1-day performance
- -2.28%
- 1-year performance
- 92.33%
- Current drawdown (1Y)
- -23.02%
- CIK
- 0001447362
- CUSIP
- 14843C105
- ISIN
- US14843C1053
- Created
- 07/12/2025, 03:28:29
- Last update
- 24/09/2026, 18:02:26
Track Castle Biosciences, Inc. with an AI analyst
See which prediction-market events move CSTL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 06:41:22
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 06/05/2026, 21:36:06
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
Zacks Investment Research • STOCK • 05/05/2026, 12:55:40
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
PRNewsWire • STOCK • 04/05/2026, 09:00:00
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
PRNewsWire • STOCK • 21/04/2026, 09:00:00
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
PRNewsWire • STOCK • 15/04/2026, 09:00:00
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
PRNewsWire • STOCK • 10/04/2026, 09:00:00
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
PRNewsWire • STOCK • 27/03/2026, 10:05:00
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
Seeking Alpha • STOCK • 23/03/2026, 22:13:39
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
GlobeNewsWire • STOCK • 13/03/2026, 12:02:00
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
GlobeNewsWire • STOCK • 03/03/2026, 17:30:00
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 26/02/2026, 21:57:54